Sutro Biopharma (STRO) 2025 Conference Summary Company Overview - Sutro Biopharma is focused on advancing its next-generation antibody-drug conjugates (ADCs) technology, aiming to differentiate from conventional ADCs and enhance commercial viability [3][4][5] Key Points and Arguments 1. **Strategic Reprioritization**: The company has deprioritized its late-stage program for loveltomab tazavibulin, focusing instead on a new pipeline strategy that emphasizes innovative ADCs [3][4] 2. **Next-Generation ADCs**: Sutro is developing ADCs targeting hard-to-reach targets, which are more complex and widely expressed across solid tumors, ensuring better commercial viability [4][5] 3. **Clinical Development Plans**: Sutro aims to deliver three Investigational New Drug (IND) applications over the next three years, starting with STRO-four in the second half of 2025, followed by STRO-six in 2026 and a dual payload ADC in 2027 [4][6] 4. **Innovative Technology**: The company claims to have one of the most powerful ADC technologies, optimizing every component of the ADC to achieve a wider therapeutic index [3][9] 5. **Dual Payload ADCs**: Sutro is focusing on dual payload ADCs, which have the potential to overcome resistance seen in single payload ADCs, providing a competitive edge in the market [6][24][25] 6. **Clinical Efficacy**: Preliminary data suggests that STRO-four has significantly higher exposure and antitumor activity compared to conventional ADCs, with a 17-fold increase in Cmax and a 50-fold increase in exposure at HNSCD [14][20] 7. **Target Selection**: The company emphasizes the importance of selecting patients based on target antigen expression, which enhances the likelihood of positive clinical outcomes [21] Additional Important Content 1. **Collaboration and Partnerships**: Sutro is collaborating with Astellas on dual payload ADCs, which is advancing rapidly and is seen as a significant opportunity for the company [26][29] 2. **Manufacturing Capabilities**: Sutro has developed a robust external CDMO network to improve cost efficiency and speed in ADC manufacturing, which supports its early pipeline [4][7] 3. **Competitive Landscape**: The ADC market is becoming congested, particularly with common targets like FR alpha, which may affect commercial viability; Sutro's focus on unique targets aims to mitigate this risk [5][6] 4. **Regulatory Simplicity**: The development of dual payload ADCs is seen as advantageous due to regulatory simplicity compared to combining multiple compounds [25][30] 5. **Pipeline Execution**: Sutro's leadership team, with extensive ADC oncology experience, is focused on executing the innovative pipeline and achieving key deliverables [31][32]

Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.95 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -44.44%. A quarter ago, it was expected that this company would post a loss of $0.86 per share when it actually produced a loss of $0.89, delivering a surprise of -3.49%.Over the last four quarters, the company has s ...

- Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline reprioritization - - Promising preclinical results with STRO-004 and dual-payload ADC, as well as STRO-006 programs presented at AACR 2025 and PEGS, respectively - - Three INDs for wholly-owned programs anticipated in next 3 years, beginning with potential best-in-class Tissue Factor ADC, STRO-004, planned for 2H 2025 - - IND-enabling toxicology study ongoing for one program within Astellas iADC ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-38662 SUTRO BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-0926186 (State ...

Exhibit 99.1 Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights SOUTH SAN FRANCISCO, Calif., May 8, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the first quarter of 2025 and recent business highlights. • In March, Sutro announced completion of a strategic portfolio review resulting in the prioritization of its wholly ...

SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in two upcoming investor conferences. Conference Details: The Citizens Life Sciences ConferenceDate: May 7-8, 2025Location: New York, NY BofA Securities 2025 Health Care ConferenceDate: May 13-15, 2025Location: Las Vegas, NV Webcasts of the pres ...

- Preclinical findings show STRO-004's promising anti-tumor activity and favorable safety profile -SOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced poster presentations at the upcoming 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30 in Chicago, IL. The presentations will cover p ...

Core Insights - Sutro Biopharma, Inc. announced expanded data from the REFRαME-O1 trial for luveltamab tazevibulin (luvelta) in patients with platinum-resistant ovarian cancer, showcasing promising results at the SGO Annual Meeting [1][2] Group 1: Clinical Data and Results - Luvelta demonstrated encouraging antitumor activity in late-stage ovarian cancer patients with Folate Receptor-α (FRα) expression of 25% or greater, achieving an overall response rate (ORR) of 32% at the optimized dose of 5.2 mg/kg [2][9] - The disease control rate (DCR) at the 5.2 mg/kg dose was 96%, compared to an ORR of 13.8% and a DCR of 69% for the 4.3 mg/kg group [9] - Safety profiles were consistent across dosing groups, with no new safety signals observed and neutropenia well-managed [9] Group 2: Treatment Implications - The data suggests potential for improved patient responses compared to standard chemotherapy, particularly for patients with FRα expression between 25% and 75%, addressing an important unmet medical need [3] - The optimized dosing regimen selected was 5.2 mg/kg + G-CSF for two cycles, followed by 4.3 mg/kg [2] Group 3: Company Strategy and Future Directions - Despite the promising data, the company announced it is deprioritizing investment in the development of luvelta across all indications and is exploring out-licensing opportunities [5] - Luveltamab tazevibulin is designed to treat a broad range of ovarian cancer patients, including those with lower FRα expression, and has received Fast Track designation from the FDA for ovarian cancer [7]

Sutro Biopharma (STRO) Q4 2024 Earnings Call March 14, 2025 04:15 PM ET Company Participants Jane Chung - Chief Executive Officer & Member, Board of DirectorsHans-Peter Gerber - Chief Scientific OfficerReni Benjamin - Managing DirectorEdward Albini - CFO Conference Call Participants Roger Song - Senior Equity Research AnalystEdward Tenthoff - Sr. Research AnalystJay Olson - Managing Director & Senior Analyst - Biotechnology Operator Welcome to the Sutro Biopharma twenty twenty five Business Update Webcast. ...

On Thursday, Sutro Biopharma, Inc. STRO prioritized its antibody-drug conjugates (ADC) pipeline, including three wholly-owned preclinical programs in its next-generation ADC pipeline.Exatecan ADC targeting Tissue Factor, STRO-004, will enter the clinic in the second half of 2025.STRO-006: Sutro’s differentiated integrin beta-6 ADC will enter clinical development in 2026, aimed at multiple solid tumors.An IND for Sutro’s first wholly-owned dual-payload ADC is anticipated to be filed in 2027.Sutro expects ope ...